Controlled delivery of TLR3 agonists in structural polymeric devices
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-038/19
A61K-039/395
A61K-045/00
A61K-031/7088
A61K-045/06
A61K-039/39
A61K-031/4745
A61K-031/708
출원번호
US-0135216
(2016-04-21)
등록번호
US-9821045
(2017-11-21)
발명자
/ 주소
Ali, Omar Abdel-Rahman
Dranoff, Glenn
Mooney, David J.
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
0인용 특허 :
43
초록
The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.
대표청구항▼
1. A device comprising a polymeric structure composition, a tumor antigen, and a TLR3 agonist, wherein said TLR3 agonist comprises condensed polyinosine-polycytidylic acid (poly I:C) cationic nanoparticles, said condensed poly I:C cationic nanoparticles being formed by mixing said poly I:C with a po
1. A device comprising a polymeric structure composition, a tumor antigen, and a TLR3 agonist, wherein said TLR3 agonist comprises condensed polyinosine-polycytidylic acid (poly I:C) cationic nanoparticles, said condensed poly I:C cationic nanoparticles being formed by mixing said poly I:C with a polycation comprising positively charged amine groups at a charge ratio resulting in positively charged condensates and an average particle size of 98-545 nm. 2. The device of claim 1, further comprising a TLR9 agonist. 3. The device of claim 1, wherein said TLR3 agonist is present at a concentration effective to induce production of interleukin-12 (IL-12) by dendritic cells. 4. The device of claim 1, wherein when the device is implanted in a subject, 200-400 ng/mL of IL-12 is produced at the site of implantation. 5. The device of claim 1, wherein the condensed poly (I:C) cationic nanoparticle comprises PEI-poly(I:C). 6. The device of claim 2, wherein the TLR9 agonist comprises a cytosine-guanosine oligonucleotide (CpG-ODN) or condensed CpG-ODN. 7. The device of claim 1, wherein the polymeric structure composition comprises poly-lactide-co-glycolide (PLG). 8. The device of claim 2, wherein the polymeric structure composition comprises poly-lactide-co-glycolide (PLG). 9. The device of claim 1, further comprising pathogen associated molecular patterns (PAMPs). 10. The device of claim 2, wherein the TLR9 agonist comprises a nucleic acid. 11. The device of claim 10, wherein the nucleic acid comprises a cytosine-guanosine oligonucleotide (CpG-ODN) or a PEI-CpG-ODN. 12. The device of claim 1, further comprising a recruitment composition. 13. The device of claim 12, wherein the recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF), Flt3L, or CCL20. 14. The device of claim 13, wherein the device comprises 0.5 μg to 500 μg of GM-CSF. 15. The device of claim 13, wherein the recruitment composition comprises encapsulated GM-CSF. 16. The device of claim 1, wherein the tumor antigen comprises a tumor lysate, purified protein tumor antigen, or synthesized tumor antigen. 17. The device of claim 1, comprising 100 μg-10,000 μg of tumor antigen. 18. The device of claim 1, wherein the tumor antigen is a lung cancer tumor antigen. 19. The device of claim 1, wherein the tumor antigen comprises an antigen from a cancer selected from the group consisting of a central nervous system (CNS) cancer, CNS Germ Cell tumor, Leukemia, Multiple Myeloma, Renal Cancer, Malignant Glioma, breast cancer, squamous cell carcinoma, ovarian carcinoma, prostate cancer, Kaposi's sarcoma, colon cancer, adenocarcinoma, testicular cancer, hepatocellular carcinoma, Synovial sarcoma, and Medulloblastoma. 20. The device of claim 2, wherein the tumor antigen comprises an antigen from a cancer selected from the group consisting of a central nervous system (CNS) cancer, CNS Germ Cell tumor, Leukemia, Multiple Myeloma, Renal Cancer, Malignant Glioma, breast cancer, squamous cell carcinoma, ovarian carcinoma, prostate cancer, Kaposi's sarcoma, colon cancer, adenocarcinoma, testicular cancer, hepatocellular carcinoma, Synovial sarcoma, and Medulloblastoma. 21. The device of claim 2, further comprising a recruitment composition. 22. The device of claim 21, wherein the recruitment composition comprises granulocyte macrophage colony stimulating factor (GM-CSF), Flt3L, or CCL20. 23. The device of claim 2, wherein the tumor antigen comprises a tumor lysate, purified protein tumor antigen, or synthesized tumor antigen. 24. The device of claim 1, wherein said polymeric structure composition is anionic and said condensed poly I:C cationic nanoparticles are electrostatically immobilized on said anionic polymeric structure composition of said device. 25. The device of claim 2, wherein said polymeric structure composition is anionic and said condensed poly I:C cationic nanoparticles are electrostatically immobilized on said anionic polymeric structure composition of said device. 26. The device of claim 1, wherein said charge ratio comprises an amino-phosphate charge ratio of 3, 4, 7, or 15. 27. The device of claim 2, wherein said charge ratio comprises an amino-phosphate charge ratio of 3, 4, 7, or 15.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Huston James S. (Chestnut Hill MA) Oppermann Hermann (Medway MA), Biosynthetic antibody binding sites.
Pardoll Drew ; Azhari Rosa,ILX ; Leong Kam W. ; Golumbe Paul K ; Jaffee Elizabeth ; Levitsky Hyam ; Lazenby Audrey, Controlled release of pharmaceutically active substances for immunotherapy.
Gaur Amitabh ; Conlon Paul ; Ling Nicholas C. ; Staehelin Theophil,CHX ; Crowe Paul D., Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
Murphy, William L.; Mooney, David J.; Kohn, David H.; Spalding, Gabriel C.; Dearing, Matthew T., Mineral and cellular patterning on biomaterial surfaces.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Hackam, David J.; Gribar, Steven C., Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.